Therapeutic results in recurrent breast cancer with the use of Bestrabucil (KM2210)
Ueda, T.; Sakai, K.; Morimoto, K.; Nakatani, S.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(12): 3285-3289
1987
ISSN/ISBN: 0385-0684 PMID: 3688892 Document Number: 299521
We administered Bestrabucil, a benzoate ester of a complex of beta-estradiol and chlorambucil, continuously to six patients with breast cancer recurrent to local and regional lymph nodes, at a dose level of 200 mg/day. Of these six cases, one achieved CR, two PR, one MR, and two were NC. The drug was thus effective in 50% of the cases, with mild side effects. At the same time, since the concentration transfer to lymph nodes was satisfactory, Bestrabucil was thought to be an effective drug for the treatment of locally recurrent breast cancer.